These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 2402946)

  • 41. Altered platelet deformability in patients with type IIa and type IV hyperlipoproteinemia.
    Smith CM; Burris SM; Hunninghake DB; White JG
    Am J Hematol; 1988 Apr; 27(4):247-52. PubMed ID: 3354559
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma cholesterol esterification rate in hyperlipoproteinaemia: relation to cholesterol elimination.
    Angelin B; Einarsson K; Leijd B; Wallentin L
    Scand J Clin Lab Invest; 1988 Sep; 48(5):481-7. PubMed ID: 3206195
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Musculoskeletal symptoms in patients with primary hyperlipoproteinemia. A prelimary study].
    Brekke SE; Kogstad OA
    Tidsskr Nor Laegeforen; 1979 Oct; 99(29):1444-6. PubMed ID: 516016
    [No Abstract]   [Full Text] [Related]  

  • 44. Sarcoidosis and acquired type II-b hyperlipoproteinaemia.
    Umeki S; Niki Y; Soejima R
    Eur Respir J; 1988 Jun; 1(6):558-9. PubMed ID: 3169225
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Role of blood insulin in the etiology of dyslipoproteinemias and ischemic heart disease in males aged 20-69 years].
    Suntsov IuI; Zhukovskii GS; Mazovetskiĭ AG; Konstantinova OS; Zinenko GM
    Kardiologiia; 1984 Nov; 24(11):36-9. PubMed ID: 6394868
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Blood and plasma hyperviscosity in primary hyperlipidemia].
    Ozanne P; Boudart D; Mainard F; Lefebvre J; Grolleau JY
    Rev Med Interne; 1984 Mar; 5(1):29-33. PubMed ID: 6718836
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Differential use of diet and drugs in dyslipoproteinemias].
    Lipovetskiĭ BM; Triufanov VF; Teriukova NP
    Klin Med (Mosk); 1985 Jan; 63(1):116-20. PubMed ID: 3990175
    [No Abstract]   [Full Text] [Related]  

  • 48. In vitro effect of p-chlormercuribenzoate upon dilute blood clot lysis time in hyperlipemia.
    Cucuianu MP; Stef C; Zdrenghea D; Popescu O
    Thromb Haemost; 1979 Oct; 42(3):929-44. PubMed ID: 505407
    [No Abstract]   [Full Text] [Related]  

  • 49. [Disorders of lipid metabolism in aseptic necrosis of the femoral head in adults].
    Biedrzycki J
    Chir Narzadow Ruchu Ortop Pol; 1990; 55(2):109-12. PubMed ID: 1369929
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Long-term effect of polyenic-fatty-acids-enriched diet on the relations of fatty acids and glycerophospholipids in 50- to 60-year-old HLP patients].
    Reuter W; Heybey U
    Z Alternsforsch; 1984; 39(2):63-6. PubMed ID: 6730529
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantification of amounts of coronary arterial narrowing in patients with types II and IV hyperlipoproteinemia and in those with known normal lipoprotein patterns.
    Cabin HS; Roberts WC
    Am Heart J; 1981 Jan; 101(1):52-8. PubMed ID: 7457340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Evaluation of the pseudocholinesterase activity in hyperlipoproteinemia type II and type IV].
    Averna MR; Montalto G; Rini GB; Di Fede G; Labisi M; Marino G; Notarbartolo A
    Boll Soc Ital Biol Sper; 1983 Apr; 59(4):520-4. PubMed ID: 6882547
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Role of excessive body weight and hormonal changes in the development of the main types of hyperlipoproteinemia].
    Kolodin VA; Gasilin VS; Baranov VA; Antonov IuS; Dokuchaeva EA
    Kardiologiia; 1984 Nov; 24(11):32-6. PubMed ID: 6394867
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Blood coagulation and fibrinolysis systems in primary hyperlipoproteinemias].
    Berent H; Uchman B
    Pol Arch Med Wewn; 1983 Sep; 70(3):131-4. PubMed ID: 6657492
    [No Abstract]   [Full Text] [Related]  

  • 55. [Effect of vitamin E on the changes in plasma lipid peroxides and platelet aggregation in patients with hyperlipoproteinemia].
    Dworski R; Domagała B; Hartwich J; Radwan J; Grzywacz M; Szczeklik A
    Pol Arch Med Wewn; 1986 Jun; 75(6):393-401. PubMed ID: 3808976
    [No Abstract]   [Full Text] [Related]  

  • 56. [Relation between hypertriglyceridemia and reduced tolerance to carbohydrates in psoriasis patients].
    Peserico A; Zanetti G; Cipriani R; Padovan S; Veller Fornasa C; Ziron L
    G Ital Dermatol Venereol; 1985; 120(1):53-4. PubMed ID: 4007936
    [No Abstract]   [Full Text] [Related]  

  • 57. [Study of the lipid levels in a case load of psoriatic patients].
    Peserico A; Zanetti G; Cipriani R; Veller Fornasa C; Ziron L; Galassini F; Pagnan A
    G Ital Dermatol Venereol; 1982; 117(1):15-7. PubMed ID: 7186877
    [No Abstract]   [Full Text] [Related]  

  • 58. Prostacyclin synthesis stimulating plasma factor in patients with primary hyperlipoproteinemia--effect of dietary and drug treatment.
    Sinzinger H; Kaliman J; Strobl-Jäger E; Widhalm K; Peskar BA
    Prostaglandins Leukot Med; 1986 May; 22(2):179-89. PubMed ID: 3523539
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hyperlipoproteinaemia and reduced fibrinolytic activity in healthy coronary high-risk men.
    Andersen P; Arnesen H; Hjermann I
    Acta Med Scand; 1981; 209(3):199-202. PubMed ID: 7223513
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Lipid metabolism in psoriasis].
    Szczeklik-Franek A; Rechowicz E
    Wiad Lek; 1976 Mar; 29(5):371-4. PubMed ID: 1258472
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.